Recent developments in U.S. patent law have seen significant actions from various legal and governmental bodies. The U.S. Patent and Trademark Office (USPTO), with insights from FoleyandLardner, MoFoLLP, and NGE_Law, is actively proposing changes aimed at reducing patent thickets and modifying terminal disclaimer practices, which could limit a patent owner's enforcement rights on patents subject to a terminal disclaimer. Concurrently, the Federal Trade Commission (FTC), as reported by FoleyHoag, has challenged several patent listings in the FDA’s Orange Book, reflecting ongoing concerns about pharmaceutical patent practices. These moves come amidst criticisms of the FDA's lack of decisive action on what should be included in the Orange Book, with experts like Tahir Amin from I-MAK calling for more leadership from the agency.
FTC Challenges More Patent Listings in the FDA’s Orange Book https://t.co/6Uy5Mz958q | by @FoleyHoag
Federal Circuit Clarifies Liability of Foreign Revenue for U.S. Domestic Patent Infringement https://t.co/lkSjZ5soYq | by @lockelord
United States Patent & Trademark Office Proposes Rule that Would Limit Patent Owner’s Enforcement Rights of Patents Subject to a Terminal Disclaimer https://t.co/Aa9fgJ3Z1w
United States Patent & Trademark Office Proposes Rule that Would Limit Patent Owner’s Enforcement Rights of Patents Subject to a Terminal Disclaimer https://t.co/GoXQrgPsBZ | by @NGE_Law
USPTO Considers Changing Terminal Disclaimer Practice To Require Agreement Regarding Enforceability https://t.co/ZiWWGDep6d | by @MoFoLLP
USPTO Aims to Mow Down Patent Thickets https://t.co/eavtYTmzDR | by @FoleyandLardner
“The FDA needs to show some leadership and say which stuff won’t go in the Orange Book, but instead, they have been flip-flopping for years,” said Tahir Amin of I-MAK.. https://t.co/Gp6fQPd6Po #pharma #FDA #patents #FTC #PTO #medicines $GSK $AZN $NVO $NOV $TEVA